Rajapaksha IG, Angus PW, Herath CB. Current therapies and novel approaches for biliary diseases. World J Gastrointest Pathophysiol 2019; 10(1): 1-10 [PMID: 30622832 DOI: 10.4291/wjgp.v10.i1.1]
Corresponding Author of This Article
Chandana B Herath, PhD, Senior Research Fellow, Department of Medicine, The University of Melbourne, Level 7, LTB, Austin Health, Heidelberg, VIC 3084, Australia. cherath@unimelb.edu.au
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Pathophysiol. Jan 5, 2019; 10(1): 1-10 Published online Jan 5, 2019. doi: 10.4291/wjgp.v10.i1.1
Current therapies and novel approaches for biliary diseases
Indu G Rajapaksha, Peter W Angus, Chandana B Herath
Indu G Rajapaksha, Chandana B Herath, Department of Medicine, The University of Melbourne, Melbourne, VIC 3084, Australia
Peter W Angus, Department of Gastroenterology and Hepatology, Austin Health, Melbourne, VIC 3084, Australia
Author contributions: Rajapaksha IG and Herath CB designed and wrote the manuscript; Angus PW contributed to the manuscript; Herath CB and Angus PW approved the final version of the manuscript.
Supported byAustralian National Health and Medical Research Council project grants, No. APP1062372 and No. APP1124125.
Conflict-of-interest statement: None
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Chandana B Herath, PhD, Senior Research Fellow, Department of Medicine, The University of Melbourne, Level 7, LTB, Austin Health, Heidelberg, VIC 3084, Australia. cherath@unimelb.edu.au
Telephone: +61-3-94962549 Fax: +61-3-94575485
Received: August 9, 2018 Peer-review started: August 9, 2018 First decision: October 19, 2018 Revised: November 1, 2018 Accepted: December 10, 2018 Article in press: December 11, 2018 Published online: January 5, 2019 Processing time: 118 Days and 1.7 Hours
Core Tip
Core tip: This mini-review focuses on the pathophysiology of chronic liver fibrosis, with a special emphasis on biliary fibrosis. We also attempted to provide information on current clinically available therapeutic options for biliary fibrosis and other potential therapeutic options that are in the preclinical stage of development, and discuss their advantages and disadvantages. In particular, work from the author’s laboratory described in this review indicates that liver-specific over-expression of angiotensin converting enzyme-2 (known as ACE2) of the alternate renin angiotensin system dramatically reduces biliary fibrosis in mouse models of biliary disease. This suggests that ACE2 gene therapy has the potential to treat patients with chronic biliary fibrosis.
